OSR Health Inc. Common Stock (OSRH)

About OSRH

OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VX…

Sector

Health Care

Industry

Medical/Dental Instruments

Employees

22

Website

osr-holdings.com/

Fundamentals

1-day range

$0.37$0.5127

Market cap

$15.32M

P/E (trailing)

12.44

P/E (forward)

—

EPS (trailing)

$-0.36

Dividend yield

—

Beta

0.49

Avg. volume

9.52M

Forecasts

1 analyst ratings

OSR Health Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• OSRH

  OSR Health Inc. Common Stock

  $0.26

  ▲ 52.94%
  Market cap $15.32MP/E 12.44
  $0.075$0.9078
• ICU

  SeaStar Medical Holding Corporation Common Stock

  $3.08

  ▼ 0.81%
  Market cap $12.19MP/E —
  $2.07$12.5
• RVP

  Retractable Technologies Inc. Common Stock

  $0.73

  ▲ 2.82%
  Market cap $20.27MP/E —
  $0.6017$1.14
• SINT

  SiNtx Technologies Inc. Common Stock

  $1.51

  ▼ 1.31%
  Market cap $10.36MP/E —
  $1.4$6.78
• CODX

  Co-Diagnostics Inc. Common Stock

  $1.2

  ▼ 4.76%
  Market cap $9.91MP/E —
  $0.9396$46.5
• PLRZ

  Polyrizon Ltd. Ordinary Shares

  $12.7

  ▼ 0.78%
  Market cap $21.51MP/E —
  $2.88$18.2
• FEMY

  Femasys Inc. Common Stock

  $3.21

  ▲ 15.05%
  Market cap $8.91MP/E —
  $2.02$22.2

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• OSR Health Subsidiary Vaximm Completes Analysis From Two Clinical Studies Evaluating VXM01 In Patients With Recurrent Glioblastoma; Data Expected To Be Submitted For Publication In The Coming Months
  Benzinga · 8/3/2026

Institutional Ownership

March 31, 2026

Total shares held

275.9K

Total value held

$161.8K

Institutional holders

10